The Top 300 of 2021. clincalc.com [online]. [cit. 2024-06-12]. Dostupné online.
doi.org
dx.doi.org
CONNOLLY, KR; THASE, ME. Vortioxetine: a New Treatment for Major Depressive Disorder.. Expert Opinion on Pharmacotherapy. 2016, s. 421–31. DOI10.1517/14656566.2016.1133588. PMID26679430.Je zde použita šablona {{Cite journal}} označená jako k „pouze dočasnému použití“.
Köhler S, Cierpinsky K, Kronenberg G, Adli M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. J Psychopharmacol. 2016 Jan;30(1):13-22. DOI:10.1177/0269881115609072Je zde použita šablona {{DOI}} označená jako k „pouze dočasnému použití“.PMID26464458
KELLINY, Marc; CROARKIN, Paul E; MOORE, Katherine M. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Therapeutics and Clinical Risk Management. 2015-08-12, roč. 11, s. 1193–1212. PMID: 26316764
PMCID: PMC4542474. Dostupné online [cit. 2024-06-12]. ISSN1176-6336. DOI10.2147/TCRM.S55313. PMID26316764.
Bang-Andersen B, Ruhland T, Jørgensen M, etal. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. Journal of Medicinal Chemistry. May 2011, s. 3206–21. DOI10.1021/jm101459g. PMID21486038.Je zde použita šablona {{Cite journal}} označená jako k „pouze dočasnému použití“.
SANCHEZ, C; ASIN, KE; ARTIGAS, F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol. Ther.. 2015, s. 43–57. DOI10.1016/j.pharmthera.2014.07.001. PMID25016186.Je zde použita šablona {{Cite journal}} označená jako k „pouze dočasnému použití“.
CONNOLLY, KR; THASE, ME. Vortioxetine: a New Treatment for Major Depressive Disorder.. Expert Opinion on Pharmacotherapy. 2016, s. 421–31. DOI10.1517/14656566.2016.1133588. PMID26679430.Je zde použita šablona {{Cite journal}} označená jako k „pouze dočasnému použití“.
Köhler S, Cierpinsky K, Kronenberg G, Adli M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. J Psychopharmacol. 2016 Jan;30(1):13-22. DOI:10.1177/0269881115609072Je zde použita šablona {{DOI}} označená jako k „pouze dočasnému použití“.PMID26464458
KELLINY, Marc; CROARKIN, Paul E; MOORE, Katherine M. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Therapeutics and Clinical Risk Management. 2015-08-12, roč. 11, s. 1193–1212. PMID: 26316764
PMCID: PMC4542474. Dostupné online [cit. 2024-06-12]. ISSN1176-6336. DOI10.2147/TCRM.S55313. PMID26316764.
Bang-Andersen B, Ruhland T, Jørgensen M, etal. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. Journal of Medicinal Chemistry. May 2011, s. 3206–21. DOI10.1021/jm101459g. PMID21486038.Je zde použita šablona {{Cite journal}} označená jako k „pouze dočasnému použití“.
SANCHEZ, C; ASIN, KE; ARTIGAS, F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol. Ther.. 2015, s. 43–57. DOI10.1016/j.pharmthera.2014.07.001. PMID25016186.Je zde použita šablona {{Cite journal}} označená jako k „pouze dočasnému použití“.
KELLINY, Marc; CROARKIN, Paul E; MOORE, Katherine M. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Therapeutics and Clinical Risk Management. 2015-08-12, roč. 11, s. 1193–1212. PMID: 26316764
PMCID: PMC4542474. Dostupné online [cit. 2024-06-12]. ISSN1176-6336. DOI10.2147/TCRM.S55313. PMID26316764.